Ingredient or product comparison
GHK-Cu for Postpartum Hair Loss Research: Study Design Comparison
In vitro (2022) Cultured dermal papilla cells 1–10 μM concentration VEGF expression, cell proliferation 230% increase VEGF; 140% proliferation vs control Demonstrates follicle-level mechanism but needs human validation RCT (2013) 20 adults with AGA, 12-week to
This source-based comparison does not add ratings or recommend a winner.
- In vitro (2022)
- Cultured dermal papilla cells
- 1–10 μM concentration
- VEGF expression, cell proliferation
- 230% increase VEGF; 140% proliferation vs control
- Demonstrates follicle-level mechanism but needs human validation
- RCT (2013)
- 20 adults with AGA, 12-week topical
- 1.5% GHK-Cu solution + liposomal carrier
- Hair density, anagen ratio
- 12.4% density increase; 15% anagen shift
- Strongest human evidence but not postpartum-specific
- Case series (2019)
- 8 women post-chemotherapy
- 2% GHK-Cu serum, twice daily
- Time to visible regrowth
- Mean 6.2 weeks earlier regrowth vs historical controls
- Suggestive for anagen induction but small sample
- Preclinical (2020)
- Mouse model, dorsal wound healing
- Subcutaneous 50 μg injection
- Follicle neogenesis markers
- 180% increase SOX9 expression; accelerated follicle cycling
- Relevant pathways but species and delivery differences limit translation